Printer Friendly

Elan reports positive data on Alzheimer's drug.

Elan Reports Positive Data on Alzheimer's Drug. Elan Corp., Ireland's biggest drugmaker, said its experimental Alzheimer's medicine will move into the last stage of testing usually required for approval. A Phase III trial of Bapineuzumab will begin in the second half of the year after an interim look at data from current studies, Dublin-based Elan and partner Wyeth (Madison NJ) said in a statement. The experimental compound, also known as AAB-001, is a humanized monoclonal antibody that received U.S. Food and Drug Administration "fast track" status, awarded to medicines that address unmet need for serious or life-threatening conditions. Analysts said it was a very positive development for both Elan and Wyeth, given that the acceleration of the drug into a Phase III study was only going to be considered if the interim data showed a significant improvement in patient progress.

Bapineuzumab is being tested in patients with mild to moderate Alzheimer's disease in two Phase II studies, Elan said. The results of the studies are not expected until 2008. More than 5 million Americans and more than 24 million people worldwide are estimated to suffer from Alzheimer's disease.
COPYRIGHT 2007 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:TOP STORIES
Article Type:Brief article
Date:Jun 4, 2007
Previous Article:Glaxo shares rebound on Avandia letter.
Next Article:Novacea Inc. (Nasdaq) led advancing issues, soaring $6.06, or 85% on the week, to $13.16.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters